

## Currently Enrolling Clinical Trials for IBC (designed for IBC patients or building on IBC research)

### Neoadjuvant trials:

*A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer*

Sites/sponsors: MD Anderson, investigator-initiated trial

Principal investigator(s): Naoto Ueno, MD PhD at MD Anderson

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT02876107>

*A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer (completed already), and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC*

Sites/sponsors: MD Anderson, investigator-initiated trial

Principal investigator(s): Bora Lim, MD at MD Anderson

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT03101748>

*TBCRC 039: Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer*

Sites/sponsors: Multi-center (8 sites) Translational Breast Cancer Research Consortium sponsored trial

Principal investigator(s): National PI is Beth Overmoyer, MD at Dana Farber

Link for information: <https://clinicaltrials.gov/ct2/show/NCT02876302>

*A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer*

Sites/sponsors: Dana Farber, investigator-initiated trial

Principal investigator(s): Beth Overmoyer, MD at Dana Farber

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT02623972>

*Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer*

Sites/sponsors: City of Hope, investigator-initiated trial

Principal investigator(s): Yuan Yuan, MD PhD at City of Hope

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT01525966>

## Adjuvant trials:

### *Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer*

Sites/sponsors: Multi-center, NCI/SWOG cooperative group sponsored trial

Principal investigator(s): National PI is Reshma Jagsi, MD at the University of Michigan

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT03598257>

### *A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy*

Sites/sponsors: MD Anderson, investigator-initiated trial

Principal investigator(s): Bora Lim, MD at MD Anderson

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT02971748>

## Metastatic trials:

### *A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy*

Sites/sponsors: MD Anderson, investigator-initiated trial

Principal investigator(s): Naoto Ueno, MD PhD at MD Anderson

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT02411656>

### *A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer*

Sites/sponsors: MD Anderson, Genentech supported, investigator-initiated trial

Principal investigator(s): Bora Lim, MD at MD Anderson

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT03202316>

### *A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial*

Sites/sponsors: Northwestern University, investigator-initiated

Principal investigator(s): Ricardo Costa, MD at Northwestern University

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT02892734>

### *A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)*

Sites/sponsors: Multi-center, company-sponsored trial (BergenBio)

Principal investigator(s): Multiple

Link for more information: <https://clinicaltrials.gov/ct2/show/NCT03184558>